Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.51%AUDCHF+0.47%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.41%EURCAD-0.36%CADJPY+0.34%AUDSGD+0.32%GBPHKD+0.32%GBPUSD+0.31%NZDSGD+0.31%NZDUSD+0.29%GBPMXN-0.28%AUDUSD+0.28%USDTRY+0.27%EURCHF+0.25%GBPJPY+0.25%CHFJPY-0.24%NZDMXN+0.23%USDNOK-0.23%EURGBP-0.23%AUDJPY+0.22%NZDJPY+0.21%USDZAR-0.21%GBPSGD+0.20%USDCHF+0.19%EURAUD-0.19%EURNZD-0.17%NOKJPY+0.17%USDSEK-0.17%CHFSGD+0.17%AUDDKK+0.16%USDILS+0.16%EURSGD+0.16%NZDCAD-0.16%USDPLN-0.16%AUDCAD-0.13%EURNOK-0.13%CHFNOK-0.12%SGDJPY-0.12%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%PLNJPY+0.10%GBPCAD-0.09%EURCNH+0.08%GBPZAR-0.08%EURUSD+0.07%EURSEK-0.06%CHFSEK-0.06%USDSGD+0.06%EURPLN-0.06%USDJPY-0.05%USDTHB+0.05%GBPAUD+0.05%USDCOP-0.04%AUDNOK+0.04%GBPNZD+0.03%USDCNH-0.02%USDMXN-0.02%EURJPY+0.02%AUDNZD+0.02%EURCZK+0.01%USDHKD+0.01%EURDKK0.00%HG1+0.79%COTTON+0.75%XNGUSD+0.42%S1+0.42%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.19%USOIL-0.15%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.08%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.82%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.34%BCHUSDT+5.78%LTCUSD+9.66%UNIUSD+7.79%SUIUSD+3.65%HBARUSDT+0.48%TONUSD+26.15%TAOUSDT+3.98%AAVEUSD+3.78%DOTUSDT+0.06%ICPUSDT+0.82%ONDOUSDT+0.53%WLDUSDT+0.17%ARBUSDT+6.90%JUPUSDT+0.62%ATOMUSDT+1.84%INJUSDT+13.93%STXUSDT+5.78%FETUSDT+3.16%TIAUSDT+9.38%PYTHUSDT-0.47%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+19.70%GRTUSDT+4.03%IOTAUSDT+1.15%WIFUSDT+2.70%AXSUSDT-1.74%POLUSDT+2.83%FARTCOINUSDT+0.81%EOSUSDT+2.46%DYDXUSDT+3.59%GALAUSDT-1.87%ORDIUSDT+0.06%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.51%AUDCHF+0.47%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.41%EURCAD-0.36%CADJPY+0.34%AUDSGD+0.32%GBPHKD+0.32%GBPUSD+0.31%NZDSGD+0.31%NZDUSD+0.29%GBPMXN-0.28%AUDUSD+0.28%USDTRY+0.27%EURCHF+0.25%GBPJPY+0.25%CHFJPY-0.24%NZDMXN+0.23%USDNOK-0.23%EURGBP-0.23%AUDJPY+0.22%NZDJPY+0.21%USDZAR-0.21%GBPSGD+0.20%USDCHF+0.19%EURAUD-0.19%EURNZD-0.17%NOKJPY+0.17%USDSEK-0.17%CHFSGD+0.17%AUDDKK+0.16%USDILS+0.16%EURSGD+0.16%NZDCAD-0.16%USDPLN-0.16%AUDCAD-0.13%EURNOK-0.13%CHFNOK-0.12%SGDJPY-0.12%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%PLNJPY+0.10%GBPCAD-0.09%EURCNH+0.08%GBPZAR-0.08%EURUSD+0.07%EURSEK-0.06%CHFSEK-0.06%USDSGD+0.06%EURPLN-0.06%USDJPY-0.05%USDTHB+0.05%GBPAUD+0.05%USDCOP-0.04%AUDNOK+0.04%GBPNZD+0.03%USDCNH-0.02%USDMXN-0.02%EURJPY+0.02%AUDNZD+0.02%EURCZK+0.01%USDHKD+0.01%EURDKK0.00%HG1+0.79%COTTON+0.75%XNGUSD+0.42%S1+0.42%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.19%USOIL-0.15%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.08%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.82%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.34%BCHUSDT+5.78%LTCUSD+9.66%UNIUSD+7.79%SUIUSD+3.65%HBARUSDT+0.48%TONUSD+26.15%TAOUSDT+3.98%AAVEUSD+3.78%DOTUSDT+0.06%ICPUSDT+0.82%ONDOUSDT+0.53%WLDUSDT+0.17%ARBUSDT+6.90%JUPUSDT+0.62%ATOMUSDT+1.84%INJUSDT+13.93%STXUSDT+5.78%FETUSDT+3.16%TIAUSDT+9.38%PYTHUSDT-0.47%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+19.70%GRTUSDT+4.03%IOTAUSDT+1.15%WIFUSDT+2.70%AXSUSDT-1.74%POLUSDT+2.83%FARTCOINUSDT+0.81%EOSUSDT+2.46%DYDXUSDT+3.59%GALAUSDT-1.87%ORDIUSDT+0.06%RONINUSDT-3.42%NOTUSDT+1.21%
VT

Voyager Therapeutics, Inc. (VYGR)

NASDAQ • Healthcare

$2.15
-$0.12 (-5.3%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$2.24
Day Range$2.14 - $2.26
Avg. Volume (3M)738.9K
Market Cap$129.9M
52 Week Range
$2.14$5.55
Next EarningsIn 26 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$3.1M100%
Gross Profitminus cost of goods$3.1M100%

Fundamentals & Financials

Revenue (TTM)
$34.4M
Net Income (TTM)
-$107.7M
EPS (TTM)
-$1.81
ROA (TTM)
-54.48%
Current Ratio
7.51

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+14.8%Q1 2026-$0.46
+13.0%Q2 2026-$0.47
+17.3%Q3 2026-$0.4
Next

Nov 9

in 26 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +17.3%

Voyager Therapeutics topped consensus EPS expectations in the second fiscal quarter of 2026, reported August 6, 2026, as EPS of -$0.40 topped the -$0.48 estimate by $0.08, while revenue fell 39% to about $3.2 million (down from roughly $5.2 million a year ago). Gross profit was about $3.2 million alongside the revenue base, and operating loss was roughly $26.4 million, with net loss narrowing 27% year over year to about $24.5 million (from roughly $33.4 million). On the bottom line, the EPS result improved ~30% from -$0.57 a year ago. The company’s quarter reflected its biotech focus on adeno-associated virus-based gene therapy programs and platform technologies for neurological diseases, including work across programs such as VY-AADC, VY-SOD102, VY-HTT01, and VY-FXN01 as well as a Tau program and spinal muscular atrophy initiatives. For the next period, consensus calls for EPS of -$0.41 on revenue of $6.3 million.

Next report — what to expect

Voyager Therapeutics, Inc. (VYGR) reports on November 9, 2026. Wall Street expects EPS of -$0.41 on revenue of $6.3 million. For trailing context, revenue fell -39.1% year over year last quarter. Voyager has beaten EPS in 5 of 8 most recent quarters, making updates on revenue and expense timing key to watch.

View full earnings history

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops adeno-associated virus-based gene therapy programs and platform technologies for neurological diseases. In FY2025, it recorded $40.4 million in revenue. Its pipeline centers on candidates for Parkinson's disease, ALS, Huntington's disease, and Friedreich's ataxia, alongside broader programs in tauopathies and spinal muscular atrophy.

Name
Voyager Therapeutics, Inc.
CEO
Alfred W. Sandrock Jr.
Website
www.voyagertherapeutics.com
Industry
Healthcare
Year Founded
2013
Employees
141

Today's Snapshot

AI-generated

The day ended with VYGR 5.3% lower at 2.15, in line with a weaker sector. VYGR closed within 0.5% of its 52-week low of 2.14.

Trading Volume

Above 10d avg 877.9K

1M

vs S&P 500 Today

Strong Underperformance

-5.27%

Updated: October 13, 2026 at 20:16 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
VYGR shows a Strong Sell stance driven by high trend strength and pervasive selling pressure despite some deeply oversold oscillators. The ADX is elevated, indicating a strong downtrend, and price is below all key moving averages including the 200-day, underscoring broad technical weakness. Short-term indicators like RSI and stochastic are in oversold territory, yet MACD and CCI remain negative and on-balance volume is strongly negative, reflecting distribution. Volatility is elevated by ATR and the pivot level lies above the current market, providing resistance. Technical takeaway: Strong Sell — robust downtrend with heavy negative volume and limited technical support.
All signals
  • EMA (5 indicators)$2.44 - $3.56
    Sell
  • RSI (14)21.30
    Buy
  • Stochastic %K (14, 3, 3)5.96
    Buy
  • MACD Level (12, 26)-0.24
    Sell

Peers & Related Assets

ALLOAllogene Therapeutics, Inc.
$1.29-7.9%
AVIRAtea Pharmaceuticals, Inc.
$4.98-1.0%
ARCTArcturus Therapeutics Holdings Inc.
$12.03-4.6%
ENTAEnanta Pharmaceuticals, Inc.
$11.52-6.3%
VNDAVanda Pharmaceuticals Inc.
$4.3-5.3%
TRDAEntrada Therapeutics, Inc.
$4.86-11.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.